Albumin-corrected anion gap (ACAG) and mortality in GI bleeding

The **albumin-corrected anion gap (ACAG)** is a calculated laboratory parameter that adjusts the traditional anion gap (a measure of the difference between measured cations and anions in the blood) for serum albumin levels. Albumin is a negatively charged protein that significantly contributes to the anion gap; therefore, low albumin levels (commonly seen in critically ill patients) can lead to an underestimation of the anion gap. Correcting the anion gap for albumin levels provides a more accurate reflection of a patient's acid-base status, which is crucial for assessing critical illnesses, including gastrointestinal bleeding (GIB).

### Role of ACAG in Mortality in GI Bleeding:

Recent research, including a retrospective cohort study analyzing data from the **Medical Information Mart for Intensive Care IV (MIMIC-IV)** database, has demonstrated that ACAG is a **powerful prognostic biomarker** for predicting mortality in critically ill patients with gastrointestinal bleeding (GIB).

#### Key Findings:

1. **Association with Mortality**:

• Elevated ACAG levels (≥20) were found to be **independently associated** with increased all-cause mortality in both short- and long-term follow-ups. This was confirmed through multivariable Cox proportional hazards regression analysis, with all results showing statistical significance (P < .001).
• Patients with higher ACAG levels had significantly lower survival rates compared to those with lower ACAG levels, as shown by Kaplan-Meier survival curves.

2. **Optimal Cutoff for Mortality Prediction**:

• Using X-tile analysis, researchers identified an **ACAG value of ≥20** as the optimal threshold for predicting 28-day mortality in GIB patients. This cutoff point allows clinicians to stratify patients into high-risk and low-risk categories.

3. **Predictive Accuracy**:

• The study demonstrated that ACAG has **moderate discriminative ability** for mortality prediction, as evidenced by receiver operating characteristic (ROC) curves.
• A predictive nomogram model incorporating ACAG achieved strong performance, with area under the curve (AUC) values for 30-, 90-, 180-, and 365-day mortality all approximately 0.80. This indicates robust predictive accuracy for both short- and long-term outcomes.

4. **Consistency Across Subgroups**:

• Subgroup analyses revealed that the prognostic value of ACAG remained consistent across diverse patient populations, further supporting its reliability as a universal risk marker in critically ill GIB patients.

5. **Linear Relationship with Mortality Risk**:

• Restricted cubic spline models confirmed a linear relationship between increasing ACAG levels and higher mortality risk. This suggests that as ACAG rises, the likelihood of mortality increases proportionally.

#### Clinical Implications:

• **Prognostic Biomarker**: ACAG can serve as a reliable and independent biomarker for identifying critically ill GIB patients at higher risk of mortality.
• **Risk Stratification**: Incorporating ACAG into clinical risk assessment tools can enhance early identification of high-risk patients, allowing for timely and targeted interventions.
• **Guidance for Treatment**: By identifying patients with elevated ACAG, clinicians can prioritize aggressive management strategies to address underlying metabolic disturbances and improve patient outcomes.

#### Summary:

The albumin-corrected anion gap (ACAG) has emerged as a critical tool for predicting mortality in gastrointestinal bleeding. Elevated ACAG (≥20) is strongly associated with worse outcomes, including both short- and long-term mortality. Its integration into clinical practice could significantly improve risk stratification and guide the management of critically ill GIB patients.